2025
Chapter 53 Tourette syndrome
Abdallah S, Fasching L, Brady M, Bloch M, Lombroso P, Vaccarino F, Fernandez T. Chapter 53 Tourette syndrome. 2025, 951-962. DOI: 10.1016/b978-0-443-19176-3.00044-3.Peer-Reviewed Original ResearchTourette syndromeCortico-striatal-thalamo-cortical circuitryStriatal volume lossAdult TS patientsNeuroimaging studiesNeuropsychiatric disordersDopaminergic receptorsVocal ticsStriatal interneuronsClasses of striatal interneuronsBasal gangliaMetabolic hypofunctionEnvironmental risk factorsTS patientsAmeliorate symptomsGenetic contributionMolecular abnormalitiesPharmacological strategiesCircuitryAffecting 1Animal modelsRisk factorsInterneuronal circuitryVolume lossAbnormalities
2020
Chapter 40 Tourette syndrome
Fasching L, Brady M, Bloch M, Lombroso P, Vaccarino F. Chapter 40 Tourette syndrome. 2020, 675-686. DOI: 10.1016/b978-0-12-813866-3.00040-0.ChaptersTourette syndromeThalamic-cortical circuitryHuman postmortem brain tissueThalamo-cortical circuitryAdult TS patientsStriatal volume lossPostmortem brain tissueEnvironmental risk factorsStriatal interneuronsDopaminergic receptorsRecurrence rateAmeliorate symptomsBasal gangliaRisk factorsFamilial recurrence ratePharmacological strategiesVocal ticsTS patientsAnimal modelsMetabolic hypofunctionComplex neuropsychiatric disorderBrain tissueMolecular abnormalitiesNeuropsychiatric disordersGenetic alterations
2017
Hippocampal Volume Changes Following Electroconvulsive Therapy: A Systematic Review and Meta-analysis
Wilkinson ST, Sanacora G, Bloch MH. Hippocampal Volume Changes Following Electroconvulsive Therapy: A Systematic Review and Meta-analysis. Biological Psychiatry Cognitive Neuroscience And Neuroimaging 2017, 2: 327-335. PMID: 28989984, PMCID: PMC5627663, DOI: 10.1016/j.bpsc.2017.01.011.Peer-Reviewed Original ResearchMajor depressive disorderElectroconvulsive therapyTotal hippocampal volumeHippocampal volumeStandardized mean differenceConsistent morphological findingsHippocampal volume increasesCognitive side effectsPre-treatment valuesHippocampal volume changesRandom-effects modelMechanism of actionClinical improvementPrimary outcomeECT treatmentDepressive disorderEffective therapyNeuroplastic processesECT studiesSide effectsAnimal modelsDepression symptomsMeta-AnalysisSystematic reviewMorphological findingsAlpha-7 nicotinic agonists for cognitive deficits in neuropsychiatric disorders: A translational meta-analysis of rodent and human studies
Lewis AS, van Schalkwyk GI, Bloch MH. Alpha-7 nicotinic agonists for cognitive deficits in neuropsychiatric disorders: A translational meta-analysis of rodent and human studies. Progress In Neuro-Psychopharmacology And Biological Psychiatry 2017, 75: 45-53. PMID: 28065843, PMCID: PMC5446073, DOI: 10.1016/j.pnpbp.2017.01.001.Peer-Reviewed Original ResearchConceptsCognitive dysfunctionAlzheimer's diseaseClinical trialsHuman studiesΑ7 nicotinic acetylcholine receptorPreclinical behavioral testsPlacebo-controlled trialMultiple clinical trialsNicotinic acetylcholine receptorsEffect sizeDrug development targetsΑ7 agonistsFunctional disabilityCochrane LibraryΑ7 nAChRsNicotinic agonistsRodent studiesTherapeutic targetAnimal modelsCurrent therapeuticsLarge effect sizesΑ7 nAChR.Acetylcholine receptorsPartial agonistBehavioral tests
2015
Chapter 107 Tourette Syndrome
Lennington J, Bloch M, Scahill L, Szuhay G, Lombroso P, Vaccarino F. Chapter 107 Tourette Syndrome. 2015, 1311-1320. DOI: 10.1016/b978-0-12-410529-4.00107-8.ChaptersTourette syndromeThalamic-cortical circuitryChildhood-onset neuropsychiatric disorderBasal ganglia circuitryStriatal interneuronsAmeliorate symptomsBasal gangliaPharmacological strategiesVocal ticsAnimal modelsPostmortem tissueNeuropsychiatric disordersSyndromeContemporary treatmentHeterogeneous disorderLarge genome-wide association studiesRecent screeningDysfunctionPotential target sitesStereotypic behaviorDisordersGenome-wide association studiesAssociation studiesChemical disruptionDopaminergic
2011
Glutamate abnormalities in obsessive compulsive disorder: Neurobiology, pathophysiology, and treatment
Pittenger C, Bloch MH, Williams K. Glutamate abnormalities in obsessive compulsive disorder: Neurobiology, pathophysiology, and treatment. Pharmacology & Therapeutics 2011, 132: 314-332. PMID: 21963369, PMCID: PMC3205262, DOI: 10.1016/j.pharmthera.2011.09.006.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderTreatment-refractory OCDGlutamate-modulating agentsSmall clinical trialsNew treatment strategiesCompulsive disorderExcitatory neurotransmitter glutamatePathophysiology of OCDGlutamate abnormalitiesGlutamate dysregulationMonoaminergic neurotransmissionCurrent therapiesClinical trialsDopaminergic neurotransmissionTreatment strategiesCognitive-behavioral psychotherapyTherapeutic benefitAnimal modelsNeurotransmitter glutamateNeurochemical investigationsPathophysiologyNew therapeuticsDisordersRecent evidenceMedications